➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PHA-793887

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug PHA-793887?

PHA-793887 is an investigational drug.

There have been 29 clinical trials for PHA-793887. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Thymoma, HIV Infections, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.

There are two US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for PHA-793887
The Benefit of Bermekimab in Patients With Systemic SclerosisHellenic Institute for the Study of SepsisPhase 2
ACTH vs Betamethasone in Hospitalized Patients With Acute GoutUniversity of PatrasN/A
The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis PatientsStem Cell and Regenerative Medicine Institute, Tabriz, IranPhase 2

See all PHA-793887 clinical trials

Clinical Trial Summary for PHA-793887

Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887

See all PHA-793887 clinical trials

US Patents for PHA-793887

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PHA-793887   Start Trial Maturation of hepatocyte-like cells derived from human pluripotent stem cells Takara Bio Europe AB (Gothenburg, SE)   Start Trial
PHA-793887   Start Trial Substituted pyrrolo-pyrazole derivatives as kinase inhibitors Pfizer Italia S.r.l. (Rome, IT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PHA-793887

Drugname Country Document Number Estimated Expiration Related US Patent
PHA-793887 China 105143445 2032-11-29   Start Trial
PHA-793887 European Patent Office 2925859 2032-11-29   Start Trial
PHA-793887 European Patent Office 3401391 2032-11-29   Start Trial
PHA-793887 Japan 2016503304 2032-11-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.